---
title: "West Pharmaceutical beats Q3 net sales estimates; lifts FY revenue, EPS outlook"
description: "West Pharmaceutical Services reported a 7.7% increase in Q3 net sales, surpassing analyst expectations. The company raised its full-year 2025 revenue guidance to $3.060-$3.070 billion and adjusted EPS"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262401666.md"
published_at: "2025-10-23T10:14:27.000Z"
---

# West Pharmaceutical beats Q3 net sales estimates; lifts FY revenue, EPS outlook

> West Pharmaceutical Services reported a 7.7% increase in Q3 net sales, surpassing analyst expectations. The company raised its full-year 2025 revenue guidance to $3.060-$3.070 billion and adjusted EPS guidance to $7.06-$7.11. Q4 2025 revenue is projected at $790-$800 million with adjusted EPS of $1.81-$1.86. The average analyst rating is "buy" with a median 12-month price target of $311.00, reflecting a 10.2% upside from the recent closing price of $279.39.

)

Overview

-   West Pharmaceutical Services Q3 net sales up 7.7%, beating analyst expectations
-   Adjusted EPS for Q3 beats consensus, reflecting strong operational performance
-   Company raises full-year 2025 revenue and EPS guidance, citing ongoing momentum

Outlook

-   West Pharmaceutical raises full-year 2025 revenue guidance to $3.060 bln-$3.070 bln
-   Company increases full-year 2025 adjusted EPS guidance to $7.06-$7.11
-   West Pharmaceutical introduces Q4 2025 revenue guidance of $790 mln-$800 mln
-   Company sets Q4 2025 adjusted EPS guidance at $1.81-$1.86

Result Drivers

-   HVP COMPONENTS GROWTH - Double-digit growth in HVP Components driven by GLP-1 products and increased HVP conversion
-   CONTRACT MANUFACTURING - Growth in Contract Manufacturing driven by self-injection devices for obesity and diabetes

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 NET Beat $804.60 $787.92

SALES mln mln (11

Analysts

)

Q3 Beat $1.96 $1.68

### ADJUSTED (12

EPS Analysts

)

### Q3 EPS $1.92

Analyst Coverage

-   The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 12 “strong buy” or “buy”, 4 “hold” and no “sell” or “strong sell”
-   Wall Street’s median 12-month price target for West Pharmaceutical Services Inc is $311.00, about 10.2% above its October 21 closing price of $279.39
-   The stock recently traded at 38 times the next 12-month earnings vs. a P/E of 33 three months ago

Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

### Related Stocks

- [WST.US - West Pharmaceutical](https://longbridge.com/en/quote/WST.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| West Pharmaceutical Services Margins Slip To 16.3% Raising Questions Around Bullish Growth Narratives | West Pharmaceutical Services reported Q3 FY 2025 revenue of $804.6 million and EPS of $1.94, showing a revenue increase  | [Link](https://longbridge.com/en/news/275848079.md) |
| Pharmaceutical Technology Excellence Awards 2025: West Pharmaceutical Services | West Pharmaceutical Services won the Product Launches award in the Prefillable Syringe Systems category at the 2025 Phar | [Link](https://longbridge.com/en/news/268025030.md) |
| REG - Morgan Stanley&CoLLC Avadel Pharma plc - Rule 38.5_A - Avadel Pharmaceuticals plc | Morgan Stanley & Co. LLC disclosed dealings related to Avadel Pharmaceuticals plc under Rule 38.5(a) of the Irish Takeov | [Link](https://longbridge.com/en/news/275721511.md) |
| REG - Morgan Stanley Cap Avadel Pharma plc - Rule 8.5_A - Avadel Pharmaceuticals plc | Morgan Stanley Capital Services LLC disclosed dealings related to Avadel Pharmaceuticals plc under Rule 38.5(a) of the I | [Link](https://longbridge.com/en/news/275421376.md) |
| REG - Rubric Capital Mgmt Avadel Pharma plc - Form 8.3 - Avadel Pharmaceuticals plc | Rubric Capital Management LP disclosed its position in Avadel Pharmaceuticals plc under Rule 8.3 of the Irish Takeover P | [Link](https://longbridge.com/en/news/275770954.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.